OSLO--(BUSINESS WIRE)--Serodus ASA (Oslo Axess: SER), a fast-growing Norwegian cardiovascular biopharma company, today announced that the company’s first clinical phase IIa study with SER100 in patients suffering from Isolated Systolic Hypertension has been initiated. The first patient has been enrolled in the study, and the company plans to enroll a total of thirty patients over the next few months. Thus, the clinical study is on schedule and Serodus expects that the last patient will be dosed in the end of the first quarter of 2014.
Help employers find you! Check out all the jobs and post your resume.
